BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 28826860)

  • 1. The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.
    Li AJ; Calvi LM
    Exp Hematol; 2017 Nov; 55():3-18. PubMed ID: 28826860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.
    Balderman SR; Li AJ; Hoffman CM; Frisch BJ; Goodman AN; LaMere MW; Georger MA; Evans AG; Liesveld JL; Becker MW; Calvi LM
    Blood; 2016 Feb; 127(5):616-25. PubMed ID: 26637787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the role of the microenvironment in MDS?
    Calvi LM; Li AJ; Becker MW
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101113. PubMed ID: 31779976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic
    Osswald L; Hamarsheh S; Uhl FM; Andrieux G; Klein C; Dierks C; Duquesne S; Braun LM; Schmitt-Graeff A; Duyster J; Boerries M; Brummer T; Zeiser R
    Mol Cancer Res; 2021 Sep; 19(9):1596-1608. PubMed ID: 34088868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
    Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
    Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow niche in the myelodysplastic syndromes.
    Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
    Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
    Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
    J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?
    Pleyer L; Valent P; Greil R
    Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27355944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.
    Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M
    Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
    Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
    Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Mesenchymal Niche in Myelodysplastic Syndromes.
    Friedrich C; Kosmider O
    Diagnostics (Basel); 2022 Jul; 12(7):. PubMed ID: 35885544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the pathogenesis of myelodysplastic syndromes.
    Delforge M
    Hematol J; 2003; 4(5):303-9. PubMed ID: 14502253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes.
    Peng H; Wen J; Zhang L; Li H; Chang CC; Zu Y; Zhou X
    Mol Biosyst; 2012 Apr; 8(4):1366-74. PubMed ID: 22327869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic Syndromes and Metabolism.
    Balaian E; Wobus M; Bornhäuser M; Chavakis T; Sockel K
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Dysfunction, Cytokine Disruption, and Stromal Changes in Myelodysplastic Syndrome: A Review.
    Lynch OF; Calvi LM
    Cells; 2022 Feb; 11(3):. PubMed ID: 35159389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications.
    Mies A; Bulycheva E; Rogulj IM; Hofbauer LC; Platzbecker U
    Curr Pharm Des; 2016; 22(16):2323-32. PubMed ID: 26916019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The functional interplay of transcription factors and cell adhesion molecules in experimental myelodysplasia including hematopoietic stem progenitor compartment.
    Daw S; Law S
    Mol Cell Biochem; 2021 Feb; 476(2):535-551. PubMed ID: 33011884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.
    Balaian E; Weidner H; Wobus M; Baschant U; Jacobi A; Mies A; Bornhäuser M; Guck J; Hofbauer LC; Rauner M; Platzbecker U
    Ann Hematol; 2019 Sep; 98(9):2063-2072. PubMed ID: 31312928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes.
    Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A
    Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.